These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 33156698)

  • 1. Voriconazole-natural latex dressings for treating infected
    Silva TVD; de Barros NR; Costa-Orlandi CB; Tanaka JL; Moro LG; Pegorin GS; Oliveira KS; Mendes-Gianinni MJ; Fusco-Almeida AM; Herculano RD
    Future Microbiol; 2020 Oct; 15():1439-1452. PubMed ID: 33156698
    [No Abstract]   [Full Text] [Related]  

  • 2. Antifungal activity of fluconazole-loaded natural rubber latex against Candida albicans.
    Yonashiro Marcelino M; Azevedo Borges F; Martins Costa AF; de Lacorte Singulani J; Ribeiro NV; Barcelos Costa-Orlandi C; Garms BC; Soares Mendes-Giannini MJ; Herculano RD; Fusco-Almeida AM
    Future Microbiol; 2018 Mar; 13():359-367. PubMed ID: 29464962
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Natural rubber dressing loaded with silver sulfadiazine for the treatment of burn wounds infected with Candida spp.
    Tanaka JL; Costa-Orlandi CB; Burd BS; Pegorin GS; da Silva TV; Guerra NB; Mendes-Giannini MJS; Fusco-Almeida AM; Herculano RD; de Barros NR
    Int J Biol Macromol; 2021 Oct; 189():597-606. PubMed ID: 34418421
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Voriconazole incorporated nanofiber formulations for topical application: preparation, characterization and antifungal activity studies against
    Esentürk İ; Balkan T; Özhan G; Döşler S; Güngör S; Erdal MS; Sarac AS
    Pharm Dev Technol; 2020 Apr; 25(4):440-453. PubMed ID: 31851857
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel polymeric dressing to the treatment of infected chronic wound.
    Garms BC; Borges FA; de Barros NR; Marcelino MY; Leite MN; Del Arco MC; de Souza Salvador SL; Pegorin GS; Oliveira KSM; Frade MAC; Herculano RD
    Appl Microbiol Biotechnol; 2019 Jun; 103(12):4767-4778. PubMed ID: 31065753
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro susceptibility of Candida spp. to fluconazole, itraconazole and voriconazole and the correlation between triazoles susceptibility: Results from a five-year study.
    Lei J; Xu J; Wang T
    J Mycol Med; 2018 Jun; 28(2):310-313. PubMed ID: 29685520
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Antifungal susceptibility profiles of Candida species to triazole: application of new CLSI species-specific clinical breakpoints and epidemiological cutoff values for characterization of antifungal resistance].
    Karabıçak N; Alem N
    Mikrobiyol Bul; 2016 Jan; 50(1):122-32. PubMed ID: 27058336
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative Study of the Effects of Fluconazole and Voriconazole on Candida glabrata, Candida parapsilosis and Candida rugosa Biofilms.
    Madhavan P; Jamal F; Pei CP; Othman F; Karunanidhi A; Ng KP
    Mycopathologia; 2018 Jun; 183(3):499-511. PubMed ID: 29380188
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro activity of anidulafungin in combination with amphotericin B or voriconazole against biofilms of five Candida species.
    Valentín A; Cantón E; Pemán J; Fernandez-Rivero ME; Tormo-Mas MA; Martínez JP
    J Antimicrob Chemother; 2016 Dec; 71(12):3449-3452. PubMed ID: 27543657
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravenous delivery of a liposomal formulation of voriconazole improves drug pharmacokinetics, tissue distribution, and enhances antifungal activity.
    Veloso DFMC; Benedetti NIGM; Ávila RI; Bastos TSA; Silva TC; Silva MRR; Batista AC; Valadares MC; Lima EM
    Drug Deliv; 2018 Nov; 25(1):1585-1594. PubMed ID: 30044149
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro studies of two triazole antifungal agents (voriconazole [UK-109,496] and fluconazole) against Candida species.
    Barry AL; Brown SD
    Antimicrob Agents Chemother; 1996 Aug; 40(8):1948-9. PubMed ID: 8843312
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [In vitro activity of voriconazole and other antifungal agents against clinical isolates of 138 Candida spp].
    Ricciardi AM; Ricciardi R; Danzi M; Mungiguerra M; Pisano L; Marino A
    Infez Med; 2009 Mar; 17(1):24-7. PubMed ID: 19359821
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [In vitro activity of fluconazole, voriconazole and posaconazole against Candida spp].
    Rubio Calvo MC; Gil J; Ramírez de Ocáriz I; Benito R; Rezusta A
    Rev Esp Quimioter; 2003 Jun; 16(2):227-32. PubMed ID: 12973462
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro susceptibility testing of Candida and Aspergillus spp. to voriconazole and other antifungal agents using Etest: results of a French multicentre study.
    Mallié M; Bastide JM; Blancard A; Bonnin A; Bretagne S; Cambon M; Chandenier J; Chauveau V; Couprie B; Datry A; Feuilhade M; Grillot R; Guiguen C; Lavarde V; Letscher V; Linas MD; Michel A; Morin O; Paugam A; Piens MA; Raberin H; Tissot E; Toubas D; Wade A
    Int J Antimicrob Agents; 2005 Apr; 25(4):321-8. PubMed ID: 15784312
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro activities of ravuconazole and voriconazole compared with those of four approved systemic antifungal agents against 6,970 clinical isolates of Candida spp.
    Pfaller MA; Messer SA; Hollis RJ; Jones RN; Diekema DJ
    Antimicrob Agents Chemother; 2002 Jun; 46(6):1723-7. PubMed ID: 12019081
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interaction of carvacroland voriconazole against drug - resistant Candida strains isolated from patients with candidiasis.
    Sharifzadeh A; Shokri H; Abbaszadeh S
    J Mycol Med; 2019 Apr; 29(1):44-48. PubMed ID: 30554935
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antifungal Activity of SCY-078 and Standard Antifungal Agents against 178 Clinical Isolates of Resistant and Susceptible Candida Species.
    Schell WA; Jones AM; Borroto-Esoda K; Alexander BD
    Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28827419
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Species distribution and antifungal susceptibility of Candida spp. causing superficial mycosis. Coro, Falcon state, Venezuela].
    Saúl-García Y; Humbría-García L; Hernández-Valles R
    Invest Clin; 2015 Sep; 56(3):276-83. PubMed ID: 26710542
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Evaluation of the VITEK 2 system (AST-YSO1 cards) for antifungal susceptibility testing against different Candida species].
    Ochiuzzi ME; Arechavala A; Guelfand L; Maldonado I; Soloaga R;
    Rev Argent Microbiol; 2014; 46(2):111-8. PubMed ID: 25011594
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improvement of the pharmacokinetic/pharmacodynamic relationship in the treatment of invasive aspergillosis with voriconazole. Reduced drug toxicity through novel rapid release formulations.
    Gallego-Arranz T; Pérez-Cantero A; Torrado-Salmerón C; Guarnizo-Herrero V; Capilla J; Torrado-Durán S
    Colloids Surf B Biointerfaces; 2020 Sep; 193():111119. PubMed ID: 32464356
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.